Stan Kaye retired as head of the Division of Clinical Studies at the Institute of Cancer Research, London in December 2013. Until 2011, he had been Head of the Drug Development Unit at Royal Marsden Hospital, one of the largest Phase I trials units in the world. He has long experience in leading on clinical trials in cancer and has most recently been involved in the development of PARP inhibitors.
He qualified in medicine in 1972 in London, and trained in medicine and oncology in London and Australia. He joined the Royal Marsden Hospital in September 2000, after 20 years at Glasgow University as Head of the Department of Medical Oncology. While there he was responsible for the move of the clinical unit at Gartnavel to the Beatson Oncology Centre at the Western Infirmary, and of the laboratory team from Horselethill Road to Garscube. He founded the Clinical Trials Unit, the Drug Development Unit and several joint clinics. His current interests, apart from new drug development, are in ovarian cancer and drug resistance.
The author of over 400 peer reviewed papers, he sits on the editorial board of 12 cancer journals, and over the past 20 years has chaired national and international committees within EORTC, MRC and CRUK.
He will continue to work at the Royal Marsden Hospital in an advisory role.
In 2013, he was appointed as senior research fellow in the Biomedical Research Centre at the Royal Marsden Hospital, and as Research Director for the West London Cancer Alliance. In this position, he is increasingly focusing on health service research in areas such as early cancer diagnosis and living with and beyond cancer.